RX pharmaceuticals

The priority goal of the company is the development and introduction to the world market of drugs based on peptide bioregulators. The company is creating 25 drugs. Currently, drugs are at different stages of pharmaceutical development and preclinical studies. 5 drugs completed the first phase of clinical trials, 1 is in the second phase.
BRAINIPEPT®
Peptide drug for adrenal glands
ELVIPEPT®
Peptide drug for gastric mucosa
CORAPEPT®
Peptide drug for heart
PANCRAPEPT®
Peptide drug for pancreas
EPINORM®
Peptide drug for epithesis
NEFROPEPT®
Peptide drug for kidneys
THYREOPEPT®
Peptide drug for thyroid gland
T-34
-
LANGOPEPT®
Peptide drug for bronchi
Партнерство
О компании
Исследования